Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00257608 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,145
- Enrollment target
NCT00257608 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 1,145 participants.
The verdict
NCT00257608, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,145 participants
- Enrollment target
Study Summary
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
Interventions
- DRUG placebo
- DRUG bevacizumab
- DRUG erlotinib HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,145 participants |
| Start Date | 2006-01 |
| Est. Completion | 2014-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00257608
The ClinicalTrials.gov registry entry for NCT00257608 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,145 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00257608 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00257608 about?
NCT00257608 is a clinical study titled "A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)". This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
What is the current status of trial NCT00257608?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,145 participants. The study started on 2006-01. Estimated completion is 2014-11.
What interventions are being tested in trial NCT00257608?
The interventions under investigation include: placebo (DRUG), bevacizumab (DRUG), erlotinib HCl (DRUG).
Who is sponsoring clinical trial NCT00257608?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.